Compare ADVB & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADVB | EVGN |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | Israel |
| Employees | N/A | 75 |
| Industry | Medical Specialities | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.1M |
| IPO Year | 2025 | N/A |
| Metric | ADVB | EVGN |
|---|---|---|
| Price | $0.26 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 38.4K | 28.1K |
| Earning Date | 02-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,016,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.19 |
| 52 Week Low | $0.25 | $0.93 |
| 52 Week High | $4.10 | $2.42 |
| Indicator | ADVB | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 62.90 |
| Support Level | $0.25 | $0.99 |
| Resistance Level | $0.35 | $1.10 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 12.17 | 69.22 |
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.